Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 2Phase 1/2 1

Status

Unknown 2Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1

Interventions

Cyclophosphamide 51fludarabine 38Injections 32Gemcitabine 25Paclitaxel 24Cisplatin 22Radiotherapy 19toripalimab 18pembrolizumab 18Carboplatin 17Capecitabine 17Fluorouracil 15Oxaliplatin 14Nivolumab 14Docetaxel 12camrelizumab 11apatinib 11Temozolomide 11Immunotherapy, Adoptive 11Cetuximab 11Bevacizumab 10Irinotecan 9Drug Therapy 9sintilimab 8Etoposide 8aldesleukin 7Taxes 7Rituximab 7Radiosurgery 7Peripheral Blood Stem Cell Transplantation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Unknown × donafenib × Clear all
NCT04472858 2022-11-29

A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1 Unknown
30 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT04059874 2019-08-16

Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate

First Affiliated Hospital of Zhejiang University

Phase 1 Unknown
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡